Trump Policies

top of page

Top 10 U.S. healthcare companies by 2026 revenue | iPharmaCenter

Top 10 U.S. healthcare companies by 2026 revenue | iPharmaCenter

Top 10 U.S. healthcare companies by 2026 revenue | iPharmaCenter

Badari Andukuri

Aug 5

CVS Pharmacy Joins Medicare GLP-1 Bridge and Scales Weight‑Loss Access Across the U.S. | iPharmaCenter

Badari Andukuri

Jun 27

Most-Favored-Nation Drug Pricing: $733B in U.S. Savings? | iPharmaCenter

Most-Favored-Nation Drug Pricing: $733B in U.S. Savings? | iPharmaCenter

Most-Favored-Nation Drug Pricing: $733B in U.S. Savings? | iPharmaCenter

Badari Andukuri

May 21

UnitedHealthcare Reduces Prior Authorization Requirements by 30% and Standardizes Electronic Submissions | iPharmaCenter

UnitedHealthcare Reduces Prior Authorization Requirements by 30% and Standardizes Electronic Submissions | iPharmaCenter

UnitedHealthcare Reduces Prior Authorization Requirements by 30% and Standardizes Electronic Submissions | iPharmaCenter

Badari Andukuri

May 12

Inside Trump’s Great Healthcare Plan: Drug Prices, Premiums, and Transparency Explained

ipharmaservices

Jan 17

GSK, Novartis, Merck, Gilead, BMS and Amgen cut US drug prices for tariff relief and massive US investment

Badari Andukuri

Dec 22, 2025

Eli Lilly Cuts Zepbound Prices on Single‑Dose Vials to Expand Obesity Drug Access in the US | iPharmaCenter

Badari Andukuri

Dec 2, 2025

NICE’s New £35k/QALY Era: Ripple Effects for Australia’s PBS and Other HTA Markets | NICE Cost Effectiveness Threshold | iPharmaCenter

NICE’s New £35k/QALY Era: Ripple Effects for Australia’s PBS and Other HTA Markets | NICE Cost Effectiveness Threshold | iPharmaCenter

NICE’s New £35k/QALY Era: Ripple Effects for Australia’s PBS and Other HTA Markets | NICE Cost Effectiveness Threshold | iPharmaCenter

Badari Andukuri

Dec 2, 2025

bottom of page